Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1034 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
filingDate |
2001-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2003-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20030074678-A |
titleOfInvention |
Human FGF23 protein mutant lowering blood phosphorus level |
abstract |
The full-length cDNA encoding the human FGF23 protein was isolated, and a variant in which one amino acid was substituted by mutagenesis was constructed. The variant had an effect of lowering the phosphorus concentration in the blood by being expressed in the body. The variant and the DNA encoding the variant are expected to be applied to therapeutic drugs or gene therapy for hyperphosphatemia. |
priorityDate |
2000-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |